All In Biotech

Drug Trial Radar · NCT06770582

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jun 3, 2025

Primary completion

Feb 1, 2032

Study completion Feb 1, 2032

Sponsor

Sponsor type
NIH
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.

Conditions

  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Stage I Bladder Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • CisplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • FluorouracilDrug

    Given IV

  • GemcitabineDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MitomycinDrug

    Given IV

  • PembrolizumabBiological

    Given IV

  • Questionnaire AdministrationOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo radiation therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bladder intact event-free survival (BIEFS)Time frame: Up to 5 years
  2. Global quality of lifeTime frame: Up to 5 years

Locations

147 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Active not recruiting

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Shaw Cancer Center

    Edwards, Colorado · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • Mount Sinai Comprehensive Cancer Center at Aventura

    Aventura, Florida · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Mount Sinai Medical Center

    Miami Beach, Florida · Recruiting

  • Grady Health System

    Atlanta, Georgia · Recruiting

  • Emory Proton Therapy Center

    Atlanta, Georgia · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Recruiting

  • Rush MD Anderson Cancer Center

    Chicago, Illinois · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois · Recruiting

  • Decatur Memorial Hospital

    Decatur, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Crossroads Cancer Center

    Effingham, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • Carle BroMenn Medical Center

    Normal, Illinois · Recruiting

  • Carle Cancer Institute Normal

    Normal, Illinois · Recruiting

  • HSHS Saint Elizabeth's Hospital

    O'Fallon, Illinois · Recruiting

  • Southern Illinois University School of Medicine

    Springfield, Illinois · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • Springfield Memorial Hospital

    Springfield, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Mary Greeley Medical Center

    Ames, Iowa · Recruiting

  • McFarland Clinic - Ames

    Ames, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa · Recruiting

  • Mercy Cancer Center-West Lakes

    Clive, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa · Recruiting

  • Iowa Methodist Medical Center

    Des Moines, Iowa · Recruiting

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.